All Type of News
“We have concern about damages of the Nagoya Protocol; the government must actively respond to it”
A request has been poured out that the government must take much aggressive positions to reduce damages which will be brought to domestic companies by the Nagoya Protocol.
During the seminar to discuss capability of ...
R&D investments of listed pharmaceutical companies remain unchanged
R&D investments of listed pharmaceutical companies have remained unchanged.
According to the analysis result of 3rd quarter’s performance reports of KOSPI and KOSDAQ listed pharmaceutical companies in 2015, the ratio...
Hanmi sees KRW 114.6 inflow, “This is the creative economy”Hanmi Pharm announced an inflow of KRW 114.6 billion by the result of a series of technology exports.
According to the official notice, Hanmi Pharm unveiled the company receive...
|
Prescriptions of risedronate sodium doubled up while alendronate sodium dropped
A research was revealed to study an aspect of prescription changes among bisophosphonate-type single drugs which have led the osteoporosis treatment market.
While a prescription rate of risedronate(original: Actonel)...
Mixed manufacturing results of different improved drugs per product
Leading improved drugs which positioned in the top 10 manufacturing performance list last year, faced mixed results in the first half.
According to the first half’s manufacturing results reported to the Ministry of F...
Only 19 companies with over 10% operating sales ratios among listed pharmaceutical companies
It was observed there were only 19 companies which exceeded 10% of operating profit ratios among listed pharmaceutical companies.
However, the pharmaceutical companies’ operating profit ratios, which were dropped due...
Reduction of sales management expenses lead to improvement of profitability
It seems listed pharmaceutical companies’ effort to reduce sales management expenses has led to improvement in profitability.
According to the Yakup Shinmoon’s analysis result of the 3rd quarter’s performance reports...
‘Velcade’ generic market of KRW 20 billion will open next year
Boryung Pharm will enter competition of Velcade(bortezomib, Janssen Korea) generics, a blockbuster multiple myeloma treatment.
According to the Ministry of Food and Drug Safety and the industry concerned on the 17th,...
Multinational pharmaceutical companies to prepare for the age of anticancer antibody
Multinational pharmaceutical companies, which entered the anticancer field with anticancer immunotherapies, have made severe competition to preoccupy the market.
Recently, MSD Korea acquired approval to conduct clini...
Peerless Aronamin and Gelfos, “Revived OTC market”
Effort of domestic pharmaceutical companies, which turned their focus towards the OTC drug industry due to the shrunken ETC drug business environment, has been slowly highlighted.
Growth of products, which stressed t...
